Alnylam Pharmaceuticals
ALNY
#575
Rank
โ‚น3.027 T
Marketcap
โ‚น23,471
Share price
-2.11%
Change (1 day)
63.44%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น355.56. In 2022 the company made an earnings per share (EPS) of -โ‚น803.69 a decrease over its 2021 EPS that were of -โ‚น622.88.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-58.04%
2022-โ‚น803.6929.03%
2021-โ‚น622.88-3.36%
2020-โ‚น644.51-8.48%
2019-โ‚น704.207.67%
2018-โ‚น654.0239.74%
2017-โ‚น468.0212.94%
2016-โ‚น414.3938.84%
2015-โ‚น298.46-32.88%
2014-โ‚น444.67259.44%
2013-โ‚น123.71-31.25%
2012-โ‚น179.9452.94%
2011-โ‚น117.6530.77%
2010-โ‚น89.97-8.77%
2009-โ‚น98.6278.13%
2008-โ‚น55.37-70.78%
2007-โ‚น189.4699.09%
2006-โ‚น95.16-43.88%
2005-โ‚น169.56-82.33%
2004-โ‚น959.70-59.23%
2003-โ‚น2,354

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น147.07-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,232-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น677.38 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.36-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น146.20-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น323.55-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น275.13-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น173.02-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel